Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer - Wikidata - thesis-toulmin - TriplyDB

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

http://www.wikidata.org/entity/Q28266580

about

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Selection and expansion of natural killer cells for NK cell-based immunotherapy Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Natural killer cell immunotherapy to target stem-like tumor cells.Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy.Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.Delivering safer immunotherapies for cancer.Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells.Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property.The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies.Natural Killer Cells - Their Role in Tumour Immunosurveillance Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Current Status of Gene Engineering Cell Therapeutics.Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity.Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives.Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment.CD8+ T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma.Immunotherapy for Gastric Cancer: Time for a Personalized Approach?Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy

P2860

Q26773135-8562EF4C-E2A8-4758-8346-042895C08744 Q26774777-F8E5502F-317A-42CA-BDD7-2723365E6A60 Q33861833-4E85AD9F-B012-44B0-80D1-420BFAB8B9A8 Q36810433-DF724818-FF1A-4008-BB10-5D3F9F03DF27 Q36853857-532B81F7-DDE3-40F6-AC71-C2F8DEB04817 Q37565475-408123CC-2830-4DCD-B3C5-EE5B5378134F Q39148267-9A90A8BE-5359-4B90-819E-6C8C4DA7687A Q39296861-45EC7D7B-466B-4E96-96B6-B5D847D2B148 Q39330984-5019FE57-92E7-44D0-9DDE-03033A0A54FA Q40081116-4960FE3B-57AE-4E37-95B2-91A8E206E094 Q41097112-61E229C1-0289-4242-B1A1-A34137EE12B0 Q41684097-91EB9613-FDC1-42BE-ACEA-4168F91C9C8F Q41684107-00E17BF1-20A5-4ABD-B925-F9A8D250BC3F Q42282419-F06BDE45-7A40-450B-86F9-7877565D1698 Q42660142-53C65B2D-B712-446B-B9C4-4EFF28B88F7F Q46350666-3AC810EE-CC47-4EDF-B874-AC04D45CD083 Q47156423-06FC64EA-881E-4661-A669-7C281704220F Q47561904-5F58A320-938B-4FA5-9CA1-817E93AD03F1 Q49829282-D3A95181-2357-4614-A2BF-7D19125D168E Q52312118-13C95E46-1C07-4D2C-A47F-F11E51999AEB Q52649735-EBE5EE67-CD98-4547-AC96-6E03DA5761C1 Q52779233-D93A92A0-7706-400B-A278-FE91D7DDDE9D Q52780137-CE6E0EB6-97B4-430F-B06A-EDFB75017E14 Q54213151-1A08AE15-1595-4FDF-AECA-2583F44FF408 Q55005404-AC185F75-D847-446E-A11C-AFB2988B19F3 Q55241239-0B398BEB-D8D3-4B5F-BE28-3DBCC6E8902F Q55243718-22961DD0-98B8-4C59-980B-80B777E0C01E Q55652343-F9B697BC-3A30-42D7-B3C3-FCBB93FD5FE5 Q58764532-766CD28C-4C9A-40C9-A8F0-48F47D917395

P2860

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

http://www.wikidata.org/entity/Q28266580

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phase I clinical trial of auto ...... with advanced digestive cancer

@ast

Phase I clinical trial of auto ...... with advanced digestive cancer

@en

Phase I clinical trial of auto ...... with advanced digestive cancer

@nl

type

label

Phase I clinical trial of auto ...... with advanced digestive cancer

@ast

Phase I clinical trial of auto ...... with advanced digestive cancer

@en

Phase I clinical trial of auto ...... with advanced digestive cancer

@nl

prefLabel

Phase I clinical trial of auto ...... with advanced digestive cancer

@ast

Phase I clinical trial of auto ...... with advanced digestive cancer

@en

Phase I clinical trial of auto ...... with advanced digestive cancer

@nl

P1433

Q28266580-A80274E2-9EA9-431E-B0C7-3CC4D7000192

P1476

Q28266580-CC1FF0B7-843B-4F22-8C1F-AD2896471004

P2093

Q28266580-10B7762A-EE7C-430D-9C3D-D50564454A0B

Q28266580-4CAECF37-4B3D-4723-AD1F-CFF37CDD8477

Q28266580-51E1335E-FA05-4CF6-B414-EC9E36BDB28C

Q28266580-528F6E23-7EB8-445B-9EB1-CBE417730EF0

Q28266580-7B85D636-EEA8-472F-84A5-A7E12C59E069

Q28266580-8BEAC242-6267-428E-AD7E-B1C0A82B989A

Q28266580-976D3443-AD1F-4E7B-B74A-AB5B7864DC61

Q28266580-9AF6C798-F208-45B7-9F86-D7FCB8CF8FB9

Q28266580-9B3B6403-B6F6-4DDE-B85C-AD14650AD900

Q28266580-AE0D95E2-B83E-4E00-B276-3DD751F52299

P2860

Q28266580-30F5784D-3169-437D-AC19-A2A5835DE4FD

Q28266580-3170D5DE-EE95-4CF3-A3C5-76A5C6E7CCE5

Q28266580-34822730-C5D8-4F56-8CEB-F22F38BE572D

Q28266580-34CBF9B2-5DE0-4E35-BAA1-ADFF7B071443

Q28266580-38CA5C0A-8554-4399-86D5-F9D2C3A8A331

Q28266580-450E3CB2-AB97-4DF0-AD08-7F238D75C185

Q28266580-59A827D6-7814-4432-B095-4E498FC6D1E9

Q28266580-609C7A91-774A-44E1-966C-23641FAFAF36

Q28266580-61956AEE-6C7F-42D0-94E9-ADFAA9B28826

Q28266580-64C505F9-B1A3-4839-801F-A168EF9691C7

P2888

Q28266580-6E5DD56A-C405-4244-9332-582E1DC3B05A

P304

Q28266580-B409876B-58C6-4705-9728-238382D79A07

P31

Q28266580-076DF38C-FE7F-4A16-A814-F247F7765480

Q28266580-6CB453D6-0A43-4348-B4A1-3D4324EE239E

P3181

Q28266580-76C469BB-5CF5-4F01-B12A-C7AD1AE57313

P356

Q28266580-C686FA34-0FBF-4D76-812D-55FFBFA221CC

P407

Q28266580-BB10A6E9-581F-48E3-9816-4D15E469F404

P433

Q28266580-C7D54C09-9373-4C37-AC33-CCE3AF79FE87

P478

Q28266580-D4541E10-E408-4920-95EC-CB48FD7D78CD

P50

Q28266580-177CEDD7-009D-4277-8381-0EF8CD578B41

P577

Q28266580-41F4819D-7A80-4D63-A455-88868336D0B8

P5875

Q28266580-5F6A34F5-B717-40BB-987E-D444B3103C28

P6179

Q28266580-AF8562D1-4B5D-4D8A-BF03-4CF332542462

P698

Q28266580-4F97A0FD-6CC0-4146-9E96-8126CF7244C5

P921

Q28266580-B574786F-5FD5-4F5E-8B9C-BD09A55455E6

P932

Q28266580-FC515B8A-4EE2-44B0-A7AB-2E3FE1EE3E50

P3181

P356

S12967-015-0632-8

P1433

Journal of Translational Medicine

P1476

Phase I clinical trial of auto ...... with advanced digestive cancer

@en

P2093

Akiko Kato

http://www.w3.org/2001/XMLSchema#string

Fumiyo Sakai

http://www.w3.org/2001/XMLSchema#string

Junichi Mineno

http://www.w3.org/2001/XMLSchema#string

Kaname Oka

http://www.w3.org/2001/XMLSchema#string

Masashige Tanabe

http://www.w3.org/2001/XMLSchema#string

Mitsuko Ideno

http://www.w3.org/2001/XMLSchema#string

Naoyuki Sakamoto

http://www.w3.org/2001/XMLSchema#string

Satoshi Kokura

http://www.w3.org/2001/XMLSchema#string

Takeshi Ishikawa

http://www.w3.org/2001/XMLSchema#string

Tatsuji Enoki

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

Nivolumab plus ipilimumab in advanced melanoma.

A new class of membrane-bound chemokine with a CX3C motif

Innate or adaptive immunity? The example of natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

P2888

s12967-015-0632-8

P304

277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2227824

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12967-015-0632-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Toshikazu Yoshikawa

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281260766

http://www.w3.org/2001/XMLSchema#string

P6179

1049799760

http://www.w3.org/2001/XMLSchema#string

P698

26303618

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4548900

http://www.w3.org/2001/XMLSchema#string